PHILADELPHIA, PA — The biotechnology firm Passage Bio, Inc. (NASDAQ: PASG) will be in the spotlight at two major investor conferences this month, offering insights into its ground-breaking genetic therapies aimed at combating neurodegenerative diseases.
The company’s management team is set to participate in the TD Cowen 44th Annual Health Care Conference on March 5, 2024, in Boston. The team will engage in a panel discussion and hold investor meetings, enhancing the dialogue around the company’s cutting-edge research and development efforts.
Following the Boston conference, Passage Bio will further extend its industry engagement at the Leerink Partners Global Biopharma Conference in Miami on March 13, 2024. Here, the team will meet with investors to discuss the company’s progress and future direction.
Both events will provide an opportunity for Passage Bio to showcase its lead product candidate, PBFT02, a one-time therapy designed to elevate progranulin levels. This innovative treatment aims to restore lysosomal function, thereby slowing disease progression in patients with neurodegenerative conditions such as frontotemporal dementia.
Investors and industry watchers unable to attend the conferences won’t be left out. A live webcast of the panel discussion at the TD Cowen conference will be available on Passage Bio’s website. A replay of the panel will also be accessible for 30 days following the event, ensuring that the company’s insights reach a wider audience.
These conferences come at a pivotal time for Passage Bio, a clinical-stage genetic medicines company dedicated to improving the lives of patients with neurodegenerative diseases. The company’s participation in these influential events underscores its commitment to advancing the field of genetic medicine and highlights the potential of its ongoing research efforts.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.